Iron Isomaltoside

Generic Name: Iron Isomaltoside

Brand Names: -

Drug Type: -

Chemical Formula: -

CAS Number: -

Unique Ingredient Identifier: -

Indication: 用于治疗以下情况的缺铁：口服铁剂无效或无法口服补铁时；临床上需要快速补充铁时。缺铁诊断必须基于实验室检查。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

IV Iron-induced Hypophosphatemia After RYGB

Phase 4

Recruiting

Conditions: Hypophosphatemia
Roux-en-Y Gastric Bypass

Interventions: Drug: Iron isomaltoside
Drug: Iron Carboxymaltose

First Posted Date: 2024-04-08

Last Posted Date: 2024-08-20

Lead Sponsor: Lucie Favre

Target Recruit Count: 94

Registration Number: NCT06350955

Locations: 🇨🇭
CHUV, Lausanne, Vaud, Switzerland

Neuroimaging Ancillary Study

Active, not recruiting

Conditions: Iron Deficiency Anemia
Iron Deficiency Anemia of Pregnancy
Child Development
Neurodevelopmental Disorder of Foetus
Iron Deficiency Anemia Treatment
Fetal Neurodevelopmental Disorder

Interventions: Drug: Ferric Sulfate
Drug: Ferric carboxymaltose
Drug: Iron isomaltoside

First Posted Date: 2022-09-19

Last Posted Date: 2024-05-24

Lead Sponsor: Thomas Jefferson University

Target Recruit Count: 184

Registration Number: NCT05545527

Locations: 🇮🇳
Jawaharlal Nehru Medical College, Belgaum, Karnataka, India

RAPIDIRON Trial Follow-up Study: RAPIDIRON-KIDS Study

Active, not recruiting

Conditions: Iron Deficiency Anemia
Neurodevelopmental Abnormality
Autism Spectrum Disorder

Interventions: Drug: Ferric carboxymaltose
Drug: Iron isomaltoside
Drug: Ferric Sulfate

First Posted Date: 2022-08-17

Last Posted Date: 2023-11-29

Lead Sponsor: Thomas Jefferson University

Target Recruit Count: 538

Registration Number: NCT05504863

Locations: 🇮🇳
Jawaharlal Nehru Medical College, Belgaum, Karnataka, India
🇮🇳
S. Nijalingappa Medical College, Bagalkot, Karnataka, India
🇮🇳
Raichur Institute of Medical Sciences, Raichur, Karnataka, India

Reducing Anemia in Pregnancy in India: the RAPIDIRON Trial

Phase 4

Completed

Conditions: Infant, Low Birth Weight
Anemia of Pregnancy
Iron Deficiency Anemia

Interventions: Drug: Ferric carboxymaltose
Drug: Iron isomaltoside
Drug: Ferric Sulfate

First Posted Date: 2022-05-03

Last Posted Date: 2024-05-24

Lead Sponsor: Thomas Jefferson University

Target Recruit Count: 4368

Registration Number: NCT05358509

Locations: 🇮🇳
Sawai Man Singh Medical College, Jaipur, Rajasthan, India
🇮🇳
Jawaharlal Nehru Medical College, Belgaum, Karnataka, India
🇮🇳
Raichur Institute of Medical Sciences, Raichur, Karnataka, India

and more 1 locations

Effect of Preoperative Iron Isomaltoside 1000 Administration on Hemoglobin Concentration in Patients Undergoing Transcatheter Aortic Valve Implantation

Phase 4

Conditions: Aortic Stenosis (Treated With TAVI)

Interventions: Drug: Normal saline
Drug: Iron isomaltoside

First Posted Date: 2020-04-15

Last Posted Date: 2020-04-30

Lead Sponsor: Yonsei University

Target Recruit Count: 214

Registration Number: NCT04346004

Locations: 🇰🇷
Department of Anesthesiology and Pain Medicine Anesthesia and Pain Research Institute Yonsei Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of

Intravenous Iron Carboxymaltose, Isomaltoside and Oral Iron Sulphate for Postpartum Anemia

Phase 3

Completed

Conditions: Iron-deficiency
Postpartum Anemia Nos

Interventions: Drug: Iron Isomaltoside
Drug: Ferrous sulphate
Drug: Iron Carboxymaltose

First Posted Date: 2019-05-21

Last Posted Date: 2022-06-27

Lead Sponsor: University Medical Centre Ljubljana

Target Recruit Count: 300

Registration Number: NCT03957057

Locations: 🇸🇮
UMC Ljubljana, Ljubljana, Slovenia

Iron Isomaltoside Compared With Iron Sucrosein Peritoneal Dialysis Patients

Not Applicable

Terminated

Conditions: Iron Deficiency Anemia Treatment

Interventions: Drug: Iron Isomaltoside
Drug: Iron sucrose

First Posted Date: 2018-08-01

Last Posted Date: 2021-10-06

Lead Sponsor: The University of Hong Kong

Target Recruit Count: 16

Registration Number: NCT03610230

Locations: 🇭🇰
Tung Wah Hospital, Hong Kong, Hong Kong

A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia Due to Inflammatory Bowel Disease

Phase 4

Completed

Conditions: IBD

Interventions: Drug: Iron Isomaltoside
Drug: Ferric Carboxymaltose

First Posted Date: 2018-03-15

Last Posted Date: 2021-02-21

Lead Sponsor: Pharmacosmos A/S

Target Recruit Count: 97

Registration Number: NCT03466983

Locations: 🇩🇰
Pharmacosmos Investigational Site, Silkeborg, Denmark

Dose-escalation Trial of the Safety, Pharmacokinetics, and Pharmacodynamics of Iron Isomaltoside (Monofer®)

Phase 1

Completed

Conditions: Anemia, Iron Deficiency
Anemia
Deficiency Diseases
Hematologic Disease
Iron Metabolism Disorders

Interventions: Drug: Iron Isomaltoside

First Posted Date: 2017-01-06

Last Posted Date: 2017-12-12

Lead Sponsor: Pharmacosmos A/S

Target Recruit Count: 24

Registration Number: NCT03013439

Locations: 🇯🇵
Ikebukuro, Tokyo, Japan

Intravenous Iron for Correction of Anaemia After Colorectal Surgery

Phase 4

Conditions: Anemia, Iron-Deficiency
Intravenous Drug Usage
Colorectal Neoplasms
Colorectal Surgery

Interventions: Drug: Saline
Drug: Iron isomaltoside

First Posted Date: 2016-12-21

Last Posted Date: 2016-12-21

Lead Sponsor: Kaunas University of Medicine

Target Recruit Count: 100

Registration Number: NCT02999217

Locations: 🇱🇹
Department of Anaesthesiology, Lithuanian University of Health Sciences, Kaunas, Lithuania

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy